Gestion De Capital Riesgo Del Pais Vasco
VC Fund
Bilbao, Spain
Gestion De Capital Riesgo Del Pais Vasco is a VC fund in Bilbao focused on Biotechnology and Health Care. Gestión de Capital Riesgo del PaÃs Vasco SGECR, S.A. is a venture capital entity management company founded in 1985 by the Basque Government as part of the Sociedad para la Promoción y Reconversión Industrial (SPRI), with the aim of promoting and developing venture capital activity in the Basque Country.
- Total investments:
- 23
- Last investment:
- Lead investor:
- 35%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Gestion De Capital Riesgo Del Pais Vasco invests in
Stages Gestion De Capital Riesgo Del Pais Vasco invests in
Countries Gestion De Capital Riesgo Del Pais Vasco invests in
Round sizes
Round size
- Seed
- $213k–$2.3M
- Series A
- $339k–$13M
Investment Focus
Industry
- Biotechnology 5 (22%)
- Health Care 4 (17%)
- Medical 3 (13%)
- Software 3 (13%)
- E-Commerce 2 (9%)
Stage
- Funding Round 8 (35%)
- Seed 6 (26%)
- Series A 2 (9%)
- Venture - Series Unknown 2 (9%)
- Pre-Seed 1 (4%)
Country
- Spain 18 (78%)
- Ecuador 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Orbik Cybersecurity provides testing and compliance services for industrial equipment and embedded electronics. | $2.3M / Seed / May 19, 2026 | ||
| InspectRail was established to offer high-quality information on the state of railway infrastructure, thereby enhancing its operation, management, and maintenance. | $357.9K / Pre-Seed / Mar 01, 2024 | ||
| Inmedical Therapeutics is centered on the creation of the Covergel product, which is intended to avoid difficulties in therapeutic endoscopies | $870.8K / Seed / Jan 17, 2024 | ||
| Irisbond creates a new way for humans to communicate through precision eye-tracking technology. Irisbond’s advanced software algorithms interpret your eye gaze in order to provide natural, intuitive and hands-free access to information and control over a screen. Developed for use in mobile devices, automotive, smart homes, robotics, scientific,healthcare and manufacturing, eye tracking technology lets you learn, play, work and communicate with your eyes. A pioneer in the assistive technology market, Irisbond’s eye tracking solutions are based on years of R&D in cooperation with Vicomtech, a leader in the field of artificial vision. For more information about the power of the eyes, go to www.irisbond.com/en | Sep 28, 2023 | ||
| Cocoon Bioscience helps catalyze the expansion of bottlenecked industries like cultivated meat by manufacturing performance and growth factors and specialized enzymes for individual protein, nutrition, and healthcare applications. | $16.1M / Venture - Series Unknown / Mar 14, 2023 | ||
| Systems and Membranes for high efficiency and purity Hydrogen production i.e. for Separation or Ammonia cracking | $13.2M / Series A / Jun 28, 2022 | ||
| Fesia Technology is working in a new generation of medical devices based on functional electrical stimulation to use in rehabilitation therapy for people who have suffered injuries and neuromuscular diseases. Based on the technology of functional electrical stimulation, Fesia has developed an innovative system of functional stimulation using anelectrode with matrix arrangement. Fesia Walk, for foot drop patients, has been already presented on the market and it is the first device of this new generetaion based on Fesia Technology. | $875.8K / Equity Crowdfunding / Feb 19, 2019 | ||
| Irisbond creates a new way for humans to communicate through precision eye-tracking technology. Irisbond’s advanced software algorithms interpret your eye gaze in order to provide natural, intuitive and hands-free access to information and control over a screen. Developed for use in mobile devices, automotive, smart homes, robotics, scientific,healthcare and manufacturing, eye tracking technology lets you learn, play, work and communicate with your eyes. A pioneer in the assistive technology market, Irisbond’s eye tracking solutions are based on years of R&D in cooperation with Vicomtech, a leader in the field of artificial vision. For more information about the power of the eyes, go to www.irisbond.com/en | $1.5M / Series B / Jan 08, 2018 | ||
| Histocell SL is a biopharmaceutical company that develops cell therapy products and novel medical devices for regenerative medicine.Histocell works to improve people’s quality of life by creating new Cell Therapy medicaments. Histocell facilities (567 m2) include a 65 m2 GMP-certified manufacturing facility for cell therapy medicinal products,and several laboratories for quality control and R&D activities. Histocell team meets the maximum quality standards through GMP and ISO 9001/2000 certifications. | $4.5M / Venture - Series Unknown / Sep 30, 2016 | ||
| Hapiick is the emergence of e-commerce as a purchase formula causes a growing demand for logistics associated with the delivery of packages to the consumer. Home deliveries are difficult for the logistics operator with a significant percentage (1 in 4) of unsuccessful attempts at delivery, which represents an inconvenience and an important handicapwith current schedules and pace of life. Happiick is proposed as an innovative service to alleviate this situation that affects a significant number of users who buy online. | $336.1K / Seed / Feb 04, 2016 | ||
| See all 23 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Gestion De Capital Riesgo Del Pais Vasco invest in?
Gestion De Capital Riesgo Del Pais Vasco invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Seed stage. Most of the 23 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Gestion De Capital Riesgo Del Pais Vasco's check size?
Gestion De Capital Riesgo Del Pais Vasco typically joins rounds of $213k–$2.3M at Seed and $339k–$13M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Gestion De Capital Riesgo Del Pais Vasco participates in.
When did Gestion De Capital Riesgo Del Pais Vasco last invest?
The most recent investment recorded for Gestion De Capital Riesgo Del Pais Vasco closed in May 2026. Shizune tracks 23 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
